SWK Holdings Corp (OQ:SWKH)

Sector:  Financials Industry:  Corporate Financial Services
 
See Regulatory Filings on SEC
Company Contact
Address: 5956 Sherry Lane, Suite 650
DALLAS TX 75225
Tel: 1-917-9306343
Website: https://www.swkhold.com
IR: See website
<
Key People
Joe D. Staggs
President, Chief Executive Officer, Interim Chief Financial and Accounting officer
   
Business Overview
SWK Holdings Corporation is engaged in specialty finance and asset management business. The Company's segments include Finance Receivables and Pharmaceutical Development. Finance Receivables segment is a healthcare capital provider, which offers customized financing solutions to a range of life science companies, institutions, and inventors. This segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Its Pharmaceutical Development segment operates through its subsidiary Enteris BioPharma, Inc. (Enteris). Enteris is a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its oral drug delivery technologies, the Peptelligence platform.
Financial Overview
For the fiscal year ended 31 December 2023, SWK Holdings Corp revenues decreased 9% to $37.8M. Net income increased 18% to $15.9M. Revenues reflect Pharmaceutical Development segment decrease of 80% to $1.2M. Net income reflects Change in fair value of acquisition-rela decrease from $5.2M (expense) to $6.3M (income), Pharmaceutical manufacturing, research decrease of 51% to $3.4M (expense).
Employees: 23 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $256.33M as of Dec 31, 2023
Annual revenue (TTM): $37.76M as of Dec 31, 2023
EBITDA (TTM): $21.18M as of Dec 31, 2023
Net annual income (TTM): $15.89M as of Dec 31, 2023
Free cash flow (TTM): $14.39M as of Dec 31, 2023
Net Debt Last Fiscal Year: $38.63M as of Dec 31, 2023
Shares outstanding: 12,497,109 as of Mar 14, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.